Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized open-label comparison of efinopegdutide versus semaglutide in NAFLD
MOH_2021-06-07_010026Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Efinopegdutide with Semaglutide (2 arms). Primary endpoints: Liver fat reduction and Fibrosis biomarkers. Started May 2021; status: completed.
02
Drugs
efinopegdutidesemaglutide
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on MOH_2021-06-07_010026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-06-07_010026.